MolecuLight Unveils Thermal Imaging for DX™ Platform, Delivering Measurement, Bacterial & Thermal Assessment in One Device, and Showcases Clinical Evidence at SAWC Spring

MolecuLight Inc. Ontario

is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

_________________________________

1 Koerner S, et al. Adv Skin Wound Care. 2019;32(7):312-320. DOI: 10.1097/01.ASW.0000559613.83195.f9.

2 Chanmugam A, et al. Adv Skin Wound Care. 2017;30(9):406-414. DOI: 10.1097/01.ASW.0000522161.13573.62.

3 Fierheller M & Sibbald RG. Adv Skin Wound Care. 2010;23(8):369-79. DOI: 10.1097/01.ASW.0000383197.28192.98.

 

Photo - https://mma.prnewswire.com/media/2676293/MolecuLight_MolecuLight_Unveils_Thermal_Imaging_for_DX__Platform.jpg

View original content:https://www.prnewswire.co.uk/news-releases/moleculight-unveils-thermal-imaging-for-dx-platform-delivering-measurement-bacterial--thermal-assessment-in-one-device-and-showcases-clinical-evidence-at-sawc-spring-302441942.html